Coventry PhD in Vascular Pharmacology: GPCR Signalling in Anthracycline-Induced Vascular Injury

Coventry PhD in Vascular Pharmacology: GPCR Signalling in Anthracycline-Induced Vascular Injury

Research Fit and Central Question

Why can an effective anticancer drug alter blood-vessel responses, and how might GPCR-linked intracellular signalling explain the injury? This Coventry MIBTP PhD connects mechanistic pharmacology with computational structural interpretation. Two directly relevant vascular studies provide a starting point, and their first author is the named early-career co-supervisor. The opportunity suits an applicant interested in experimental and quantitative drug-safety research. Its central scientific test is to distinguish receptor signalling, direct drug binding and human clinical benefit, rather than assume that evidence for one establishes the others.

The Coventry project information dated October 2026 lists this project with a 23 November 2026 deadline and no closing time. Present availability is unconfirmed; verify the opportunity before applying. Coventry explicitly covers the international tuition-fee difference alongside UKRI maintenance support. This is competitive funding, with limited international awards, rather than a personal award already secured. The immediate next step is to check Chinese qualification equivalence and prepare the exact PGR+ application, while asking how the experimental and computational supervision will be divided.

Research Problem and Doctoral Work

Anthracycline-associated cardiovascular toxicity includes a vascular component: blood vessels can respond differently to normal regulatory signals after drug exposure. The advertised question concerns GPCRs and their downstream signalling, not simply whether a drug damages cells. A convincing explanation must connect a receptor-dependent functional change to a specific intracellular mechanism and establish how far that mechanism generalises across models.

The advertised doctoral work has three connected elements: cellular models of receptor signalling, comparison of intracellular responses associated with drug-induced vascular injury, and computational structural assessment of possible drug–receptor interactions. The project seeks common mediators rather than promising that every affected receptor behaves identically. These are proposed research activities; a validated screening platform, protective treatment or diagnostic test is not an established outcome of the studentship.

The existing papers make this distinction particularly important. Vascular contraction is a functional readout, whereas receptor expression, localisation and pathway activity describe different biological levels. A change in one does not automatically explain all the others. Computationally plausible receptor interaction would generate a hypothesis; it would not establish direct binding or account for a whole-vessel response by itself. The thesis could therefore contribute a carefully bounded mechanistic account and a model-validation framework even if a universal mediator is not found.

Useful research questions include which effects are reproducible across independent biological preparations, which depend on model context, and whether apparent pathway involvement survives alternative explanations such as general cellular stress. These are analytical priorities, not additional advertised work packages. The scientific value lies in separating mechanisms with interpretable evidence, rather than treating a predicted interaction as a therapeutic result. The official project and supervision outline supports this mechanistic focus.

School, Programme and Field Context

Coventry University is the registering institution. The exact PGR+ opportunity identifies CHLR002, under the older “Centre for Health and Life Sciences – Discovery Biology and Therapeutics” label. The university and staff pages cited here use Centre for Discoveries in Life Sciences (DLS). The final formal award wording and individual registration date should be confirmed; participation in a six-university training partnership does not imply a joint degree.

MIBTP provides a four-year training framework, with the network advertising October 2027 entry; the individual registration date remains to be confirmed. Its FAQ describes cross-university training, a three-month research placement away from the home institution, a three-month technical mini-project and three-month PIPS. The detailed training framework instead gives the technical visit a range of one day to three months, alongside quantitative, modelling and cohort training. That page retains a 2025 cohort heading; confirm the personal 2027 timetable rather than assuming three fixed three-month placements. This project appears in Coventry’s standard PhD table, separately from its CASE table; the longer CASE placement range should not be transferred to it. Training mobility is a substantive commitment, with location and practical costs to clarify.

The DLS environment combines cell biology, biochemistry, pharmacology and physiology. Its institutional description includes industrial collaboration and Royal Society of Biology doctoral-training accreditation under a legacy centre name. These are relevant environmental signals, although they do not establish an individual student’s equipment allocation or a pharmacology subject ranking. QS World University Rankings 2027 places Coventry at =581 overall. That broad position is weaker than the most internationally prominent research universities; this opportunity’s more specific case rests on the project’s publication continuity, supervision and funded interdisciplinary training. No verified subject-specific ranking for this laboratory was established.

Supervisor and Lab Assessment

Hardip Sandhu’s institutional profile identifies her as Assistant Professor Research, DLS, accepting PhD students. Her programme concerns therapy-induced cardiovascular injury, vascular GPCR signalling and safety-pharmacology screening. The formal MIBTP page names Dr Caroline Lozahic as this project’s secondary supervisor. Lozahic is listed as a Research Fellow, with first authorship on the two central vascular studies. This provides unusually direct methodological continuity, while her day-to-day responsibilities and contract coverage remain questions for interview.

Three recent original studies genuinely include Sandhu:

Lozahic and colleagues (2024): receptor-dependent vascular function

Lozahic and colleagues, 2024, rat coronary GPCR responses, corresponds to PMID 38326659, DOI 10.1007/s00210-024-02988-x. The original abstract reports receptor-dependent changes in coronary contraction following doxorubicin exposure. It establishes the functional starting point for the PhD, while leaving downstream mechanism and human relevance unresolved.

Lozahic and colleagues (2025): MEK1/2-linked responses

Lozahic and colleagues, 2025, MEK1/2-linked coronary responses, DOI 10.1016/j.ejphar.2025.178162, was online on 15 September 2025 and published in the 5 November 2025 issue. The advert’s “EJP final revision” status is therefore outdated. The study links several functional responses to MEK1/2, but the ETB response direction differs from the earlier abstract. A blanket claim that all GPCR responses increase would lose that distinction. Both papers arise from the same research line, not independent external replication.

Kuburas and colleagues (2022): adjacent cardiac safety evidence

Kuburas and colleagues, 2022, AMPK and sunitinib-associated cardiac injury, DOI 10.1097/FJC.0000000000001256, examines pathway-associated protection in rat-heart and cellular models. Sandhu is a named last/corresponding author. It demonstrates adjacent safety-pharmacology experience and the difficulty of balancing cardiac protection with anticancer activity. It concerns a different drug and myocardial setting, so it does not validate the proposed anthracycline–vascular GPCR mechanism.

Sandhu’s published supervision commitments include weekly meetings, a minimum weekly face-to-face contact, mixed meeting formats, a shared rota for time-sensitive work and two weeks’ notice for feedback on writing up to 5,000 words. Initial training is personally supported. These are useful expectations to discuss alongside co-supervisor availability, computational mentoring, assay access and technical support. Clinical/industrial links on staff pages indicate a research network, not guaranteed patient data, a placement host or commercial access for this student.

Funding, Application, and Living Cost

The Coventry MIBTP programme information explicitly combines UK-rate tuition, Coventry’s payment of the international fee difference and tax-free UKRI maintenance. It quotes £21,805 for 2026/27, plus travel/conference and consumables budgets without amounts. A MacBook Pro is available for use during the programme. The 2027 stipend, individual award dates and precise funded months remain to be confirmed against the four-year framework; their absence does not remove the positive international funding route.

The MIBTP application rules allow international and overseas-qualified applicants, with up to 30% of awards available to international students across the network. This is a cap, not an admission probability or a project-specific allocation. Studentships are awarded through candidate competition; the FAQ warns that a shortlisted candidate may have to choose another project if the preferred one is unavailable.

Complete the ED&I expression-of-interest form and the Coventry application through this project’s PGR+ link by 23 November 2026. The ED&I responses are separated from academic shortlisting. General Coventry PGR guidance requests degree documentation and, for non-English degree documents, the originals plus notarised English translations. It also permits two academic references or one academic plus one professional reference. Referee email requests follow submission; personal-email references and editable Word references are not accepted. MIBTP’s general guidance mentions CV, cover letter and references; the project-specific application checklist should resolve any additional statement or proposal requirement. A proposal is conditional in the general guide, not automatically mandatory here. Katie.Choudhry@coventry.ac.uk handles advertised administrative enquiries; research.admissions@coventry.ac.uk appears on PGR+.

Cycle Works accommodation lists £154–£210 weekly at 2026/27 prices, with 39-, 43- and 50-week contracts, including utilities, Wi-Fi and contents insurance. At 50 weeks, rent alone is £7,700–£10,500. Extending those weekly rates to 52 weeks is a budgeting assumption, not an offered contract: £8,008–£10,920. Adding an analyst scenario of £450–£600 monthly for food, local transport and other non-rent spending gives £13,408–£18,120 annually. The dated stipend could cover that scenario, with differing headroom; deposits, travel, placement-related accommodation and 2027 price changes need separate provision.

International students pay travel, visa and health-surcharge costs themselves. The cited government information lists a £558 Student visa fee and a £776 annual student IHS rate; the amount paid upfront depends on visa length and charging rules. These are dated policy references, not guaranteed 2027 charges. Student visa sponsorship requires the usual CAS and immigration evidence.

Applicant Fit and Preparation

The advertised academic minimum is a relevant UK 2:1 first degree, with wording about 60% in the project element, or equivalent with a 60% overall module average. Coventry should clarify how those clauses apply to the individual qualification; they are not a claim that a Chinese 60% average qualifies. MIBTP separately evaluates overseas equivalents and discusses stronger/less strong 2:1 backgrounds and exceptional additional experience. Coventry’s research entry rules allow relevant master’s qualifications to be considered where the first degree is below 2:1, with a minimum Merit (60%) overall and in the dissertation or equivalent under the general rule; competitive selection still applies.

Chinese applicants have a positive route through overseas-degree equivalence, explicit international fee-gap coverage and the Student visa system. The university’s China qualification section recognises Chinese degree documents, but its generic “Postgraduate” 70% entry line does not establish this PhD’s Chinese percentage threshold. Supply the grading scale, transcript, degree and research-project evidence for a project-specific assessment.

Coventry’s call and relevant centre English table specify IELTS Academic 7.0 overall, each 6.5, or TOEFL iBT 95 overall, each 21. At application, Coventry requires evidence of meeting English requirements or booking an approved test. The network FAQ allows scores later, but retains old October 2026 wording and permits waivers only in exceptional mitigating circumstances; confirm the 2027 procedure with the host. The cited research guidance requires English qualifications within the two years preceding the proposed start. Its stated exemption concerns recent UK-degree-level English-medium education in a UKVI majority-English-speaking country; a Chinese English-medium degree is not automatically exempt. Confirm the accepted 2027 TOEFL scale and test provision against the offer rather than importing another university’s score. ATAS applicability depends on the actual research subject/CAH and nationality; Chinese nationality is not exempt, but no project-specific CAH decision was established.

Pharmacology, physiology, biochemistry, molecular bioscience and quantitatively oriented life-science backgrounds are relevant. Receptor signalling, quantitative analysis or structural-modelling experience would help, but the advert does not make prior mastery of every technique a separate requirement. Useful preparation is a clear explanation of a previous research question, appropriate controls, uncertainty and reproducibility, plus evidence of learning across experimental and computational work. A purely computational expectation with no interest in biological validation would fit the advertised balance poorly.

Career Relevance

ABPI’s 2025 talent analysis identifies persistent data/digital and computational skills gaps. That supports the transferability of quantitative pharmacology and model evaluation, rather than proving a salary premium or guaranteed role. Plausible pathways include academic mechanistic research, preclinical safety assessment and assay/model development; clinical practice requires separate qualifications.

Next Actions and Questions to Verify

Before applying: obtain confirmation of Chinese qualification equivalence and English-test treatment; use CHLR002 and the exact PGR+ title, complete ED&I, and allow time for references before the date-only deadline. Check the checklist for a CV, cover letter or additional statement rather than assuming an independent research proposal is compulsory. Scientific enquiries can use hardip.sandhu@coventry.ac.uk, corroborated in the 2025 primary publication record; administrative questions belong to the advertised Coventry contacts.

At interview: clarify how Sandhu and Lozahic divide daily supervision; what independent evidence will distinguish receptor/pathway effects from model-wide injury; who supports structural computation; and what equipment, technical assistance and data are actually allocated. Ask how the 2024/2025 receptor-dependent differences influence the starting hypothesis. Discuss a tractable thesis if direct drug binding or a common mediator is not supported.

Before accepting: confirm the formal award wording, registration/start date, individual stipend and funded term, travel/placement budgets, international fee coverage for the full supported period, and any extension costs. Obtain realistic training/placement locations, IP and publication terms. Personal award details belong to offer assessment; applicants need not already hold an award to enter this competition.

Evidence and Sources

Present vacancy availability and current administrative terms are unconfirmed. The evidence for all three studies covers complete institutional abstracts and publication identities; full main texts, supplementary data and raw datasets are outside its scope. This limits detailed assessment of controls, statistical power and reproducibility.

Project, institution and training

• Coventry exact project in the 2027 MIBTP call
• Exact PGR+ project and CHLR002 registration route
• Hardip Sandhu institutional research profile
• Sandhu exact MIBTP supervision, co-supervisor and registration
• Caroline Lozahic role and doctoral lineage
• DLS official research environment and doctoral training context
• QS Coventry University 2027 overall ranking

Original research

• Doxorubicin alters GPCR-mediated vasocontraction in rat coronary arteries
• Doxorubicin coronary GPCR vasoconstriction via MEK1/2
• Metformin protects against sunitinib cardiotoxicity: AMPK

Funding, applications, costs and career context

• MIBTP 2027 application and international eligibility
• Detailed MIBTP training and technical-visit duration
• MIBTP FAQ training, fees and selection rules
• Coventry research entry and centre-specific English requirements
• Coventry research application documents and PGR+ procedure
• Coventry Cycle Works accommodation costs and contract scope
• UK Student visa route
• UK immigration health surcharge
• ATAS nationality and covered subject rules
• ABPI 2025 primary global talent and skills analysis
• Coventry China qualification page: postgraduate scope boundary
• Coventry official country and contact address